Sandoz has launched a generic version of Novartis' Exelon Patch for Alzheimer's dementia.
Sandoz has launched a generic version of Novartis’ Exelon Patch for Alzheimer’s dementia.
The generic rivastigmine transdermal system is indicated to treat mild, moderate, and severe memory problems associated with Alzheimer’s disease. The patch can also be used to treat patients with mild to moderate dementia associated with Parkinson’s disease.
Rivastigmine is the only Alzheimer's disease treatment in the form of a patch.
Because the incidence and severity of serious stomach side effects like nausea, vomiting, and ulcers are dose related, rivastigmine should be initiated at a dose of 4.6 mg every 24 hours and then titrated to a dose of 9.5 mg every 24 hours. If appropriate, the dose can be increased to 13.3 mg every 24 hours.
Sandoz is marketing its generic rivastigmine in a 13.3 mg strength, the same as brand-name Exelon Patch.
Rivastigmine patch treatment should be discontinued if the patient experiences a skin reaction that spreads beyond the size of the patch; has blisters, swelling, or redness; or does not get better within 48 hours of patch removal.